<DOC>
	<DOC>NCT02143284</DOC>
	<brief_summary>EndoChoice's FUSE System enables a wider view range via 1-2 additional cameras (depending on the model). These optical properties are to be examined and reviewed in this trial (mainly usability and safety)</brief_summary>
	<brief_title>A Study of EndoChoice's Upper&amp;Lower Endoscopic Systems Utilizing a Full Spectrum Optical Technology</brief_title>
	<detailed_description>EndoChoice Full Spectrum Optical Technology (FSOT) in gastrointestinal endoscopy enables a 330 degree field of view. FSOT powers EndoChoice's FDA, CE and AMAR (Israeli medical device authority) approved Endoscopic systems (Gastroscope and Colonoscope). The intent of this study is to evaluate the safety, performance and usability of additional versions of FSOT- powered gastroscopes and colonoscopes.</detailed_description>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<criteria>Male and Female patients ages of 1870 The patient has been scheduled for routine screening upper or lower endoscopy, diagnostic endoscopic work up, or endoscopic surveillance. Signed informed consent Patients with inflammatory bowel disease; Patients with a personal history of polyposis syndrome; Patients with suspected bowel stricture potentially precluding complete endoscopy Patients with a history of diverticulitis or toxic megacolon Patients with a history of radiation therapy to neck, abdomen, pelvis; Patients who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the patient's participation in this study. Patients with GI bleeding, that has not been corrected prior to endoscopy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>